Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$153.61
Open:$152.08
Day's Low:$151.23
Day's High:$156.98
Bid / Ask:-
Market Cap:10.74B
Enterprise Value:11.13B
52-Week Range
52-Week Low:$126.40
52-Week High:$354.88
Current position in 52-week range
52w Low-52w High
50-Day Avg:$141.02
200-Day Avg:$178.13
Volume
Volume Today:1,614,276
Avg Volume (3m):1,698,726
Avg Volume (10d):1,186,430
52-Week Change:-52.04%
vs S&P 500, 52 weeks:-
Beta:1.05
Valuation Multiples
P/E (trailing):29.00
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.
P/E (forward):20.05
PEG Ratio:1.21
Price / Book:7.55
Price / Sales (TTM):3.52
EV / Revenue:3.65
EV / EBITDA:18.11
Dividends
Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):3.05B
Gross Profit:2.17B
EBITDA:614.90M
Net Income (TTM):375.30M
Rev Growth (YoY):+23.50%
Earnings Growth (YoY):+328.60%
Quarterly earnings growth (YoY):+322.20%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$5.34
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$7.72
Revenue Per Share:$43.62
Cash Per Share:-
Book Value:$20.51
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:534.90M
Total Debt:1.02B
Net Debt (Debt - Cash):480.60M
Debt / Equity:71.40%
Current Ratio:2.49
Quick Ratio:1.51
Cash Flows
Operating Cash Flow:511.20M
Free Cash Flow (FCF):236.90M
FCF Yield (FCF / Market Cap):-
Enterprise Value:11.13B
EV / Revenue:3.65
EV / EBITDA:18.11
Profitability
ROE (Return on Equity):26.02%
ROA (Return on Assets):9.72%
P/E (trailing):29.00
P/E (forward):20.05
Price / Book:7.55
PEG Ratio:1.21
52-Week Change:-52.04%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$5.34
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$7.72
P/E (forward):20.05
PEG Ratio:1.21
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$43.62
Cash Per Share:-
Book Value:$20.51
Cash Flows (TTM)
Free Cash Flow:236.90M
Operating Cash Flow:511.20M
EBITDA:614.90M
Total Revenue (TTM):3.05B
Net Income (TTM):375.30M
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:69,354,199
Float (free shares):69,062,911
Short interest (shares):5,629,649
Short % of float:-
Short Ratio (days to cover):3.51
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Insulet Corporation (PODD) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Senior VP and Chief Quality, Regulatory & Compliance Officer
-
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
Insulet Corporation (PODD): Quantitative Analysis
Insulet Corporation (PODD) — Healthcare — Medical Devices. PODD is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, PODD has returned −45.5% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
PODD ranks 404 of 461 on today's multifactor score, and 51 of the 55 Healthcare companies that score. Its strongest factor is growth (Z 0.33, ranked 97 of 489); its weakest is momentum (Z -1.62, ranked 484 of 494). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
According to Nasdaq's public calendar (checked on Nov 4, 2026), Insulet will report its next earnings on Nov 4, 2026, before the US market opens. The date is announced by the company itself and can change. Of its last 12 earnings announcements: 7 after the close and 5 before the open (SEC filings through Aug 5, 2026). PODD earnings dates and times, quarter by quarter →
What is Insulet's P/E ratio?
Insulet's P/E (price over earnings per share for the last twelve months) is 29.0 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Jun 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Insulet is below its sector median. Healthcare stocks, company by company →
Where does Insulet rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Insulet ranks 404 of 461, and 51 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Insulet insiders bought or sold shares?
The latest open-market purchase of Insulet shares filed with the SEC (Form 4) was on Aug 21, 2026, by a director who is also an officer, for $162k. The latest sale was on Jun 3, 2026, by a director, for $60k. In total, from August 2025 through Nov 3, 2026: 6 purchases and 4 sales by directors, officers and large shareholders. All PODD insider trades →
What sector is Insulet in, and which index?
Insulet is classified in the Healthcare sector (industry: Medical Devices), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.